Evidence map›Paper›PMID 41731244›Full record

ArticleCPT: pharmacometrics & systems pharmacology2026

Integrating B Cell Differentiation Model With Real-World Data Informs Determinants for Antibody-Secreting Cell Depletions in Systemic Sclerosis.

Tomohisa Nakada, Ryuta Saito, Sho Ishigaki, Hiroshi Takei, Keiko Yoshimoto, Mitsuhiro Akiyama, Tsutomu Takeuchi, Yuko Kaneko, Fumihiko Miyoshi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CPT: pharmacometrics & systems pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tomohisa NakadaDiscovery Technology Laboratories, Research Division, Tanabe Pharma Corporation, Yokohama, Japan.ORCID https://orcid.org/0000-0003-0519-6543
Ryuta SaitoDiscovery Technology Laboratories, Research Division, Tanabe Pharma Corporation, Yokohama, Japan.ORCID https://orcid.org/0000-0002-4782-1469
Sho IshigakiDivision of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Keio University, Tokyo, Japan.ORCID https://orcid.org/0009-0001-3100-9011
Hiroshi TakeiDivision of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Keio University, Tokyo, Japan.ORCID https://orcid.org/0000-0001-5167-0715
Keiko YoshimotoDivision of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Keio University, Tokyo, Japan.ORCID https://orcid.org/0000-0002-6491-267X
Mitsuhiro AkiyamaDivision of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Keio University, Tokyo, Japan.ORCID https://orcid.org/0000-0001-5075-8977
Tsutomu TakeuchiDivision of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Keio University, Tokyo, Japan.ORCID https://orcid.org/0000-0003-1111-8218
Yuko KanekoDivision of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Keio University, Tokyo, Japan.ORCID https://orcid.org/0000-0003-2646-5765
Fumihiko MiyoshiDiscovery Technology Laboratories, Research Division, Tanabe Pharma Corporation, Yokohama, Japan.ORCID https://orcid.org/0009-0004-5010-8295

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic sclerosis (SSc) is a complex autoimmune disorder characterized by extensive fibrosis, vascular abnormalities, and immune dysregulation, affecting clinical outcomes such as skin thickness and pulmonary function with high mortality rates. B cells play a pivotal role in the pathogenesis of SSc. This study aimed to develop a systems model for B cell differentiation and tissue distribution to characterize the therapeutic responses to CD19

Indexed as

Antibodies, Monoclonal, HumanizedAntibody-Producing CellsB-LymphocytesModels, BiologicalRituximabScleroderma, SystemicAntigens, CD19Antigens, CD20Cell DifferentiationComputer SimulationFemaleHumansMaleMiddle AgedAntibodies, Monoclonal, HumanizedAntigens, CD19Antigens, CD20inebilizumabRituximabimmunologymechanism‐based pharmacokinetics‐pharmacodynamicsmonoclonal antibodiespersonalized medicinephysiology‐based pharmacokineticsquantitative pharmacologysystems pharmacology

Identifiers

PMID41731244
PMCPMC12962402

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.